Evidence Comparison
Both are widely discussed online for recovery, but neither is an FDA-approved medicine and neither has the kind of robust human evidence available for established therapies.
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Compound class | Synthetic peptide | Thymosin-beta-4-related research peptide |
| Regulatory status | Not FDA approved | Not FDA approved |
| Evidence | Primarily preclinical; limited human evidence | Primarily preclinical / investigational |
| Key point | Online claims exceed clinical evidence | Do not infer efficacy from thymosin-beta-4 biology alone |
How to interpret this comparison
A comparison should not be read as a recommendation to use either compound. The more important questions are whether the product is approved for the intended use, whether controlled human evidence exists, and whether safety is understood well enough for clinical decision-making.
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.